Publication:
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers

dc.contributor.authorMyron M. Levineen_US
dc.contributor.authorSalim Abdullahen_US
dc.contributor.authorYaseen M. Arabien_US
dc.contributor.authorDelese Mimi Darkoen_US
dc.contributor.authorAnna P. Durbinen_US
dc.contributor.authorVicente Estradaen_US
dc.contributor.authorEuzebiusz Jamroziken_US
dc.contributor.authorPeter G. Kremsneren_US
dc.contributor.authorRosanna Lagosen_US
dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.authorStanley A. Plotkinen_US
dc.contributor.authorRobert Sauerweinen_US
dc.contributor.authorSheng Li Shien_US
dc.contributor.authorHalvor Sommerfelten_US
dc.contributor.authorKanta Subbaraoen_US
dc.contributor.authorJohn J. Treanoren_US
dc.contributor.authorSudhanshu Vratien_US
dc.contributor.authorDeborah Kingen_US
dc.contributor.authorShobana Balasingamen_US
dc.contributor.authorCharlie Welleren_US
dc.contributor.authorAnastazia Older Aguilaren_US
dc.contributor.authorM. Cristina Cassettien_US
dc.contributor.authorPhilip R. Krauseen_US
dc.contributor.authorAna Maria Henao Restrepoen_US
dc.contributor.otherFaculty of Tropical Medicine, Mahidol Universityen_US
dc.contributor.otherRegional Centre for Biotechnologyen_US
dc.contributor.otherCentro para Vacunas en Desarrollo Chileen_US
dc.contributor.otherKing Saud bin Abdulaziz University for Health Sciencesen_US
dc.contributor.otherIfakara Health Instituteen_US
dc.contributor.otherUniversitetet i Bergenen_US
dc.contributor.otherWuhan Institute of Virology Chinese Academy of Sciencesen_US
dc.contributor.otherUniversidad Complutense de Madriden_US
dc.contributor.otherOrganisation Mondiale de la Santéen_US
dc.contributor.otherUniversity of Melbourneen_US
dc.contributor.otherUniversity of Rochester Medical Centeren_US
dc.contributor.otherUniversitätsklinikum und Medizinische Fakultät Tübingenen_US
dc.contributor.otherBill and Melinda Gates Foundationen_US
dc.contributor.otherWellcome Trusten_US
dc.contributor.otherMonash Universityen_US
dc.contributor.otherNational Institute of Allergy and Infectious Diseases (NIAID)en_US
dc.contributor.otherRadboud Universiteiten_US
dc.contributor.otherUniversity of Maryland School of Medicineen_US
dc.contributor.otherFood and Drug Administrationen_US
dc.contributor.otherUniversity of Pennsylvaniaen_US
dc.contributor.otherJohns Hopkins Bloomberg School of Public Healthen_US
dc.contributor.otherWHO RandD Blueprint COVID-19 Vaccines Working Groupen_US
dc.contributor.otherCentre de Recherches Médicales de Lambarénéen_US
dc.date.accessioned2022-08-04T09:23:31Z
dc.date.available2022-08-04T09:23:31Z
dc.date.issued2021-06-01en_US
dc.description.abstractWHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a "rescue treatment"to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.en_US
dc.identifier.citationClinical Infectious Diseases. Vol.72, No.11 (2021), 2035-2041en_US
dc.identifier.doi10.1093/cid/ciaa1290en_US
dc.identifier.issn15376591en_US
dc.identifier.issn10584838en_US
dc.identifier.other2-s2.0-85094964919en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/78189
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85094964919&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleViewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteersen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85094964919&origin=inwarden_US

Files

Collections